HUP0300547A2 - Ciano-kinolin vegyületek alkalmazása vastagbél polipok kezelésére és gátlására alkalmas gyógyszerkészítmények előállítására - Google Patents
Ciano-kinolin vegyületek alkalmazása vastagbél polipok kezelésére és gátlására alkalmas gyógyszerkészítmények előállításáraInfo
- Publication number
- HUP0300547A2 HUP0300547A2 HU0300547A HUP0300547A HUP0300547A2 HU P0300547 A2 HUP0300547 A2 HU P0300547A2 HU 0300547 A HU0300547 A HU 0300547A HU P0300547 A HUP0300547 A HU P0300547A HU P0300547 A2 HUP0300547 A2 HU P0300547A2
- Authority
- HU
- Hungary
- Prior art keywords
- alkyl
- carbon atoms
- amino
- methyl
- carbon
- Prior art date
Links
- WDXARTMCIRVMAE-UHFFFAOYSA-N quinoline-2-carbonitrile Chemical class C1=CC=CC2=NC(C#N)=CC=C21 WDXARTMCIRVMAE-UHFFFAOYSA-N 0.000 title abstract 2
- 208000035984 Colonic Polyps Diseases 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- -1 hydroxy methyl- Chemical group 0.000 abstract 11
- 125000004432 carbon atom Chemical group C* 0.000 abstract 6
- 229910052799 carbon Inorganic materials 0.000 abstract 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000005042 acyloxymethyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000005422 alkyl sulfonamido group Chemical group 0.000 abstract 1
- 125000005133 alkynyloxy group Chemical group 0.000 abstract 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004970 halomethyl group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 208000014081 polyp of colon Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- General Preparation And Processing Of Foods (AREA)
- Compounds Of Unknown Constitution (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52419600A | 2000-03-13 | 2000-03-13 | |
| PCT/US2001/007068 WO2001068186A2 (en) | 2000-03-13 | 2001-03-06 | Use of cyanoquinolines for treating or inhibiting colonic polyps |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0300547A2 true HUP0300547A2 (hu) | 2003-07-28 |
Family
ID=24088181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0300547A HUP0300547A2 (hu) | 2000-03-13 | 2001-03-06 | Ciano-kinolin vegyületek alkalmazása vastagbél polipok kezelésére és gátlására alkalmas gyógyszerkészítmények előállítására |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP1263503B1 (enExample) |
| JP (1) | JP2003526686A (enExample) |
| KR (2) | KR20080009294A (enExample) |
| CN (1) | CN1190197C (enExample) |
| AR (1) | AR035482A1 (enExample) |
| AT (1) | ATE308364T1 (enExample) |
| AU (2) | AU2001245452B2 (enExample) |
| BR (1) | BR0109165A (enExample) |
| CA (1) | CA2402742C (enExample) |
| DE (1) | DE60114580T2 (enExample) |
| DK (1) | DK1263503T3 (enExample) |
| EA (1) | EA200200976A1 (enExample) |
| ES (1) | ES2248302T3 (enExample) |
| HK (1) | HK1048775B (enExample) |
| HU (1) | HUP0300547A2 (enExample) |
| IL (2) | IL151249A0 (enExample) |
| MX (1) | MXPA02008836A (enExample) |
| NO (1) | NO20024356L (enExample) |
| NZ (1) | NZ521117A (enExample) |
| PL (1) | PL202873B1 (enExample) |
| TW (1) | TWI262805B (enExample) |
| WO (1) | WO2001068186A2 (enExample) |
| ZA (1) | ZA200208178B (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6576644B2 (en) | 2000-09-06 | 2003-06-10 | Bristol-Myers Squibb Co. | Quinoline inhibitors of cGMP phosphodiesterase |
| US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
| US7084156B2 (en) | 2001-11-27 | 2006-08-01 | Merck & Co., Inc. | 2-Aminoquinoline compounds |
| WO2003064399A1 (fr) * | 2002-01-28 | 2003-08-07 | Ube Industries, Ltd. | Procede de production de derive de quinazolin-4-one |
| AU2003217323A1 (en) * | 2002-02-05 | 2003-09-02 | Wyeth | Process for the synthesis of n-acyl-2-amino-4-alkoxy-5-nitrobenzoic acids |
| US7009053B2 (en) * | 2002-04-30 | 2006-03-07 | Yungjin Pharmaceuticals Co., Ltd. | Quinoline derivatives as caspase-3 inhibitor, preparation for producing the same and pharmaceutical composition comprising the same |
| DE10221018A1 (de) | 2002-05-11 | 2003-11-27 | Boehringer Ingelheim Pharma | Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie |
| ES2400339T3 (es) | 2002-07-15 | 2013-04-09 | Symphony Evolution, Inc. | Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer |
| US7109337B2 (en) | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| GEP20084357B (en) | 2002-12-20 | 2008-04-29 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| WO2006074147A2 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics, Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
| US8309562B2 (en) | 2003-07-03 | 2012-11-13 | Myrexis, Inc. | Compounds and therapeutical use thereof |
| JP5129957B2 (ja) | 2003-07-03 | 2013-01-30 | ミリアド ジェネティクス， インコーポレイテッド | カスパーゼの活性化因子およびアポトーシスの誘発因子としての４−アリールアミノ−キナゾリン |
| EP2392565B1 (en) | 2003-09-26 | 2014-03-19 | Exelixis, Inc. | c-Met modulators and methods of use |
| TW200529846A (en) | 2004-02-20 | 2005-09-16 | Wyeth Corp | 3-quinolinecarbonitrile protein kinase inhibitors |
| AU2005231507B2 (en) | 2004-04-08 | 2012-03-01 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
| MXPA06011658A (es) | 2004-05-14 | 2006-12-14 | Pfizer Prod Inc | Derivados de pirimidina para el tratamiento del crecimiento celular anormal. |
| CA2564199A1 (en) | 2004-05-14 | 2005-11-24 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| EP1751142A1 (en) | 2004-05-14 | 2007-02-14 | Pfizer Products Incorporated | Pyrimidines derivatives for the treatment of abnormal cell growth |
| US8258145B2 (en) | 2005-01-03 | 2012-09-04 | Myrexis, Inc. | Method of treating brain cancer |
| RU2007140957A (ru) * | 2005-05-25 | 2009-06-27 | Вайет (Us) | Способы синтеза производных 6-алкиламинохинолинов |
| JP5191391B2 (ja) | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
| JP5688877B2 (ja) | 2005-11-11 | 2015-03-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌疾患の治療用キナゾリン誘導体 |
| DE102006029445A1 (de) * | 2006-06-21 | 2007-12-27 | Bayer Schering Pharma Ag | Neue 3-Cyano-chinoline als Kinase-Inhibitoren |
| DE102006029446A1 (de) * | 2006-06-21 | 2007-12-27 | Bayer Schering Pharma Ag | Neue 3-substituierte-Chinoline als Kinase-Inhibitoren |
| ES2385613T3 (es) | 2006-09-18 | 2012-07-27 | Boehringer Ingelheim International Gmbh | Método para tratar cánceres que portan mutaciones de EGFR |
| DE102007024470A1 (de) | 2007-05-24 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Neue Sulfoximin-substituierte Chinolin- bzw. Chinazolinderivate als Kinase-Inhibitoren |
| EP2072502A1 (de) | 2007-12-20 | 2009-06-24 | Bayer Schering Pharma Aktiengesellschaft | Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren |
| PT2387563E (pt) | 2009-01-16 | 2013-03-25 | Exelixis Inc | Sal de malato de n-(4-{[6,7-bis(metiloxi)quinolin-4- il]oxi}fenil)-n¿-(4-fluorofenil)ciclopropano-1,1-dicarboxamida, e suas formas cristalinas para o tratamento de cancro |
| MX2011013666A (es) * | 2009-06-25 | 2012-03-06 | Amgen Inc | Compuestos heterociclicos y sus usos. |
| SI2451445T1 (sl) | 2009-07-06 | 2019-07-31 | Boehringer Ingelheim International Gmbh | Postopek za sušenje BIBW2992, njegovih soli in trdnih farmacevtskih formulacij, ki obsegajo to aktivno sestavino |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| AU2010363329A1 (en) | 2010-11-07 | 2013-05-09 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| UY35464A (es) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| US9242965B2 (en) | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
| JP6533997B2 (ja) * | 2014-12-26 | 2019-06-26 | 株式会社ヤクルト本社 | Ｚｎｆ１４３阻害活性を有する化合物およびその利用 |
| MX382355B (es) * | 2015-04-10 | 2025-03-13 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos. |
| US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058902A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| WO2017058807A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| MX2018005967A (es) | 2015-11-16 | 2018-08-29 | Araxes Pharma Llc | Compuestos de quinazolina 2-sustituida que comprenden un grupo heterociclico sustituido y metodos de uso de los mismos. |
| US11279689B2 (en) | 2017-01-26 | 2022-03-22 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer |
| EP3573964A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Benzothiophene and benzothiazole compounds and methods of use thereof |
| WO2018140512A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| EP3573970A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
| US11059819B2 (en) | 2017-01-26 | 2021-07-13 | Janssen Biotech, Inc. | Fused hetero-hetero bicyclic compounds and methods of use thereof |
| MX2019013954A (es) | 2017-05-25 | 2020-08-31 | Araxes Pharma Llc | Inhibidores covalentes de kras. |
| JP2020521740A (ja) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | 変異体ｋｒａｓ、ｈｒａｓまたはｎｒａｓの調節因子としてのキナゾリン誘導体 |
| CN110869357A (zh) | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | 化合物及其用于治疗癌症的使用方法 |
| KR20210045998A (ko) | 2018-08-01 | 2021-04-27 | 아락세스 파마 엘엘씨 | 헤테로사이클릭 스피로 화합물 및 암 치료를 위한 그의 사용 방법 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA73073C2 (uk) * | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| DE60031127T2 (de) * | 1999-08-12 | 2007-02-01 | Wyeth Holdings Corp. | Nsaid und egfr kinase inhibitoren enthaltende pharmazeutische formulierung zur behandlung oder inhibierung von dickdarmpolypen und kolorektalem krebs |
-
2001
- 2001-03-06 WO PCT/US2001/007068 patent/WO2001068186A2/en not_active Ceased
- 2001-03-06 HU HU0300547A patent/HUP0300547A2/hu unknown
- 2001-03-06 IL IL15124901A patent/IL151249A0/xx active IP Right Grant
- 2001-03-06 AU AU2001245452A patent/AU2001245452B2/en not_active Ceased
- 2001-03-06 DE DE60114580T patent/DE60114580T2/de not_active Expired - Lifetime
- 2001-03-06 NZ NZ521117A patent/NZ521117A/en unknown
- 2001-03-06 ES ES01918367T patent/ES2248302T3/es not_active Expired - Lifetime
- 2001-03-06 PL PL363072A patent/PL202873B1/pl not_active IP Right Cessation
- 2001-03-06 MX MXPA02008836A patent/MXPA02008836A/es active IP Right Grant
- 2001-03-06 KR KR1020077027115A patent/KR20080009294A/ko not_active Ceased
- 2001-03-06 EA EA200200976A patent/EA200200976A1/ru unknown
- 2001-03-06 AU AU4545201A patent/AU4545201A/xx active Pending
- 2001-03-06 HK HK03101049.6A patent/HK1048775B/en not_active IP Right Cessation
- 2001-03-06 KR KR1020027012074A patent/KR100817423B1/ko not_active Expired - Fee Related
- 2001-03-06 BR BR0109165-4A patent/BR0109165A/pt not_active Application Discontinuation
- 2001-03-06 AT AT01918367T patent/ATE308364T1/de not_active IP Right Cessation
- 2001-03-06 EP EP01918367A patent/EP1263503B1/en not_active Expired - Lifetime
- 2001-03-06 JP JP2001566747A patent/JP2003526686A/ja not_active Withdrawn
- 2001-03-06 CN CNB018093981A patent/CN1190197C/zh not_active Expired - Fee Related
- 2001-03-06 DK DK01918367T patent/DK1263503T3/da active
- 2001-03-06 CA CA002402742A patent/CA2402742C/en not_active Expired - Fee Related
- 2001-03-12 AR ARP010101143A patent/AR035482A1/es not_active Application Discontinuation
- 2001-03-12 TW TW090105702A patent/TWI262805B/zh active
-
2002
- 2002-08-14 IL IL151249A patent/IL151249A/en not_active IP Right Cessation
- 2002-09-12 NO NO20024356A patent/NO20024356L/no unknown
- 2002-10-10 ZA ZA200208178A patent/ZA200208178B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1263503A2 (en) | 2002-12-11 |
| PL202873B1 (pl) | 2009-07-31 |
| PL363072A1 (en) | 2004-11-15 |
| DE60114580T2 (de) | 2006-07-27 |
| MXPA02008836A (es) | 2003-02-10 |
| KR20020092987A (ko) | 2002-12-12 |
| KR100817423B1 (ko) | 2008-03-27 |
| NO20024356L (no) | 2002-11-12 |
| CA2402742C (en) | 2009-05-12 |
| AU4545201A (en) | 2001-09-24 |
| DE60114580D1 (de) | 2005-12-08 |
| DK1263503T3 (da) | 2006-02-13 |
| CN1190197C (zh) | 2005-02-23 |
| IL151249A (en) | 2008-06-05 |
| CN1429126A (zh) | 2003-07-09 |
| NO20024356D0 (no) | 2002-09-12 |
| HK1048775A1 (en) | 2003-04-17 |
| KR20080009294A (ko) | 2008-01-28 |
| HK1048775B (en) | 2006-01-20 |
| CA2402742A1 (en) | 2001-09-20 |
| JP2003526686A (ja) | 2003-09-09 |
| ATE308364T1 (de) | 2005-11-15 |
| AR035482A1 (es) | 2004-06-02 |
| ZA200208178B (en) | 2004-02-11 |
| IL151249A0 (en) | 2003-04-10 |
| EP1263503B1 (en) | 2005-11-02 |
| EA200200976A1 (ru) | 2003-02-27 |
| BR0109165A (pt) | 2003-04-22 |
| TWI262805B (en) | 2006-10-01 |
| WO2001068186A3 (en) | 2002-01-17 |
| NZ521117A (en) | 2005-02-25 |
| AU2001245452B2 (en) | 2005-05-05 |
| WO2001068186A2 (en) | 2001-09-20 |
| ES2248302T3 (es) | 2006-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0300547A2 (hu) | Ciano-kinolin vegyületek alkalmazása vastagbél polipok kezelésére és gátlására alkalmas gyógyszerkészítmények előállítására | |
| RU2395500C2 (ru) | 2,4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств | |
| JO2372B1 (en) | Source drugs of 4-phenylpyridine derivatives | |
| MY141661A (en) | 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
| DE69923849D1 (de) | Quinolin-2-on-derivate verwendbar als antikrebsmittel | |
| AP2001002079A0 (en) | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents. | |
| MY138252A (en) | Azabicyclic-substitud fused-heteroaryl compounds for the treatment of disease | |
| JO2282B1 (en) | Oxazole derivatives | |
| ATE361287T1 (de) | Neue indol-2-on derivate | |
| MXPA05006420A (es) | Derivados de pirimidina para el tratamiento de crecimiento celular anormal. | |
| YU95102A (sh) | Supstituisani biciklični derivati u lečenju abnormalnog rasta ćelija | |
| HUP0401889A2 (hu) | 1,8-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények | |
| HUP0103063A2 (hu) | Új 2H-piridazin-származékok, alkalmazásuk, ilyen hatóanyagot tartalmazó gyógyászati készítmények, és eljárás a hatóanyag előállítására | |
| HUP0401729A2 (hu) | IV típusú foszfodiészteráz inhibitor hatású alkin-aril-naftiridin-4(1H)-on-származékok és ezeket tartalmazó gyógyszerkészítmények | |
| DE602004017479D1 (de) | Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon | |
| MA29213B1 (fr) | Quinolones a substitution macrolones - amino | |
| CY1110343T1 (el) | 2-(πυριδιν-2-υλο)-πυριμιδινες και η χρησιμοποιηση του για την καταπολεμηση επιζημιων μυκητων | |
| IL184116A0 (en) | Use of thiazolidinone derivatives as antiangiogenic agents | |
| DE60102171D1 (de) | Ketolidantibiotika | |
| NO20034301L (no) | Cyano-substituerte dihydropyrimidin forbindelser | |
| MXPA04003611A (es) | Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes. | |
| BRPI0407441A (pt) | 4-[(2,4-dicloro-5-metóxifenil)amino]-6-alcóxi-3-quinoli nacarbonitrilos para o tratamento de lesão isquêmica | |
| TW200716527A (en) | Substituted aminoalkyl-and amidoalkyl-benzopyran derivatives | |
| HUP0401687A2 (hu) | Szteroid-szulfatáz inhibitor acil-szulfonamidok és ezeket tartalmazó gyógyszerkészítmények | |
| ATE509905T1 (de) | Benzamidderivate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |